Negative conversion – Page 2 – Communicable Diseases Research

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients

Azvudine은 COVID-19 환자 치료에 효과적인 흉선 유도 항 SARS-CoV-2 약물입니다.

Article

Published on 2021-12-062022-09-10
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 임상, 치료법, 치료제,

Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series

Case Report

Published on 2021-11-232022-10-30
Journal: Journal of Medical Case Reports [Category] COVID-19, MERS, SARS,

Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence

COVID-19 관리에서 항바이러스제로서의 락토페린: 예비 증거

Article

Published on 2021-10-192022-09-10
Journal: International Journal of Environmental Research an [Category] MERS, SARS, 치료제,

[키워드] added adverse event adverse events Analysis antiviral activity Antiviral effect Asymptomatic Asymptomatic COVID-19 bovine bovine lactoferrin cationic clinical symptom conducted COVID-19 COVID-19 negative COVID-19 patient COVID-19 patients D-dimer D-dimers exocrine gland exocrine glands ferritin glycoprotein healthy subject Hospitalized hospitalized patient IL-6 in vitro in vivo intranasal Isolation lactoferrin liposomal bovine lactoferrin management medication Mild-to-moderate multifunctional Negative conversion Neutrophils observation Patient patients recruited reported SARS-CoV-2 SARS-CoV-2 RNA Serum ferritin significant decrease Standard of care three groups treated
[DOI] 10.3390/ijerph182010985 PMC 바로가기 [Article Type] Article

Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

COVID-19 환자에 대한 Shuanghuanglian 경구 액체의 효과: 무작위, 공개, 병행 대조, 다기관 임상 시험

Randomized Controlled Trial

Published on 2021-10-012022-09-11
Journal: Frontiers of medicine [Category] SARS, 유전자 메커니즘, 임상,

[키워드] 95% CI Absorption addition baseline Chest computed tomography Chinese clinical trial Combination composed Computed tomography conducted control group COVID-19 disease dose Effect effective evaluated groups High dose High-dose Inflammatory low dose mean difference multicenter Multicenter trial Negative conversion nucleic acid occurred Open-label Patent Medicine Patient Pneumonia promoted Randomized reduction Safe SARS-CoV-2 Serious Adverse Event Serious Adverse Events Shuanghuanglian oral liquid significantly significantly higher standard care Standard therapy Swab test the patient Treatment
[DOI] 10.1007/s11684-021-0853-6 PMC 바로가기 [Article Type] Randomized Controlled Trial

Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study

COVID-19 환자를위한 폐렴-표적 Lopinavir/Ritonavir 기반 치료 : 초기 기간 후 향적 단일 센터 관찰 연구

Observational Study

Published on 2021-09-142022-09-10
Journal: BMC Infectious Diseases [Category] SARS, 임상, 치료제,

[키워드] 95% CI 95% confidence interval Administered age antiviral therapy Antiviral treatment approach Asymptomatic center Chain Reaction Computed tomography coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 discharged evidenced Hospitalization Hospitalized Increasing increasing age initial likelihood Lopinavir Lopinavir/ritonavir management median medical record medical records Negative conversion Odds ratio oxygen oxygen supplementation Patient patients with COVID-19 PCR Pneumonia pneumonic polymerase chain polymerase chain reaction Probability respiratory respiratory symptom Result retrospective Ritonavir Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 significant delay significantly significantly higher single center Symptomatic treatment the patient Treatment Treatment outcome two group two groups virological outcomes Virus shedding
[DOI] 10.1186/s12879-021-06588-5 PMC 바로가기 [Article Type] Observational Study

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

Article

Published on 2021-08-122022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] 95% confidence interval acute respiratory syndrome adverse event Analysis antiviral agent Antiviral agents assigned Ciclesonide clinical clinical trial conducted coronavirus coronavirus disease COVID-19 Diagnosis drug effective Efficacy enrolled evaluate evaluated groups High-flow nasal oxygen inhalation inhaler inhibit intravenous mechanical ventilation Mild-to-moderate multicenter nasopharyngeal viral load Negative conversion Open-label Patient per day Phase 2 polymerase chain primary endpoint progression Quantitative Randomized Randomly receive Registration Respiratory failure reverse transcription SARS-CoV-2 SARS-CoV-2 viral shedding significantly higher significantly lower standard care study enrollment symptom onset therapy treat Treatment
[DOI] 10.3390/jcm10163545 PMC 바로가기 [Article Type] Article

Therapeutic efficacy of macrolides in management of patients with mild COVID-19

가벼운 Covid-19 환자의 관리에서 마크로 라이드의 치료 효능

Randomized Controlled Trial

Published on 2021-08-112022-08-13
Journal: Scientific Reports [Category] MERS, 신약개발, 임상, 진단, 치료법, 치료제,

[키워드] addition Anosmia Azithromycin biochemical evaluation blood count C-reactive protein CBC Chain Reaction Chest computed tomography Chest CT clarithromycin complete blood count Computed tomography control group cough COVID-19 CRP D-dimer Dyspnea Efficacy Fever gastrointestinal tract management Mild Molecular biology Molecular medicine Negative conversion no significant difference Patient patients treated patients with COVID-19 PCR performed polymerase chain reaction protocol randomized trial real-time reverse transcription-polymerase chain reaction regimen Registered rRT-PCR SARS-CoV-2 PCR Serum ferritin significant difference standard care Standard of care study participant Study participants supportive care Symptom Symptomatic treatment therapeutic three group three groups Treatment treatment regimen Trial registration
[DOI] 10.1038/s41598-021-95900-z PMC 바로가기 [Article Type] Randomized Controlled Trial

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis

코로나19 환자에서 아르비돌(우미페노비르)의 효능 및 안전성: 체계적인 고찰 및 메타분석

Review

Published on 2021-08-042022-09-10
Journal: Immunity, Inflammation and Disease [Category] SARS, 치료제,

[키워드] (Umifenovir 2019 novel coronavirus infection 2019‐nCoV infection 95% confidence interval Adding adverse event Arbidol benefit carried Chloroquine Cochrane Library coronavirus COVID‐19 Day disease Efficacy Efficacy and safety Evidence inclusion criteria Lopinavir Lopinavir/ritonavir mean difference medRxiv Negative conversion no significant difference Novel coronavirus objective Patient PCR Primary outcome Primary outcomes Result risk risk of bia risk ratio Ritonavir secondary outcome Secondary outcomes significant difference systematic review therapeutic agent therapeutic agents therapeutic effect Treatment treatment group umifenovir was performed were used
[DOI] 10.1002/iid3.502 PMC 바로가기 [Article Type] Review

Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials

2019년 코로나바이러스 질병 가이드라인에서 권장하는 32가지 약리학적 중재의 비교 효과 및 안전성: 66건의 시험을 결합한 체계적인 검토 및 네트워크 메타 분석

Meta-Analysis

Published on 2021-07-272022-09-11
Journal: Chinese medical journal [Category] meta-analysis, SARS,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adverse event Antibiotics antiviral agent Antiviral agents assessment Bayesian framework calculated Chinese Chloroquine ClinicalTrials Cochrane Library Comparative coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids COVID-19 cure cure rate development drug effect size Effectiveness Efficacy and safety eight evaluate Evidence followed by global pandemic health problem IFN include increased risk interferon interferons low dose measure moderate Mortality Negative conversion Network meta-analysis Odds ratio other treatments Patient patients with COVID-19 pharmacological intervention pharmacological interventions Primary outcome public health Randomized controlled trial Randomized controlled trials RCT RCTs reduce mortality reduction respiratory risk searched severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 standard care Standard of care systematic review TCM Traditional Chinese medicine Trial Viral was performed
[DOI] 10.1097/CM9.0000000000001672 PMC 바로가기 [Article Type] Meta-Analysis

The correlation between mental health status, sleep quality, and inflammatory markers, virus negative conversion time among patients confirmed with 2019-nCoV during the COVID-19 outbreak in China: An observational study

Observational Study

Published on 2021-07-092022-10-05
Journal: Medicine [Category] SARS, 임상,

[키워드] 2019 coronavirus disease 2019-nCoV Analysis Anxiety Clinical characteristics collected conducted correlation COVID-19 COVID-19 outbreak cross-sectional survey Depression depressive dimension disorder immune function index indicated Inflammation Inflammatory inflammatory markers Inflammatory response information Laboratory Lymphocyte count mental health Negative conversion neutrophil count NLR participant Patient Pittsburgh platform positively correlated problem problems Psychological Quality questionnaire reported Self-Rating Depression Scale significant difference Sleep Sleep disturbance sleep quality spread to Stress Symptom total score virus was increased
[DOI] 10.1097/MD.0000000000026520 PMC 바로가기 [Article Type] Observational Study